The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated survival analysis of patients (pts) with unresectable (UR) or borderline resectable (BR) locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX.
Moh'd M. Khushman
No relevant relationships to disclose
Peter Joel Hosein
No relevant relationships to disclose
Michel Velez
No relevant relationships to disclose
Lauren Carcas
No relevant relationships to disclose
Daniel Joseph Dammrich
No relevant relationships to disclose
Jorge Hurtado-Cordovi
No relevant relationships to disclose
Ritesh Parajuli
No relevant relationships to disclose
Terri Pollack
No relevant relationships to disclose
Jessica Macintyre
No relevant relationships to disclose
Ana Paula P. Harwood
No relevant relationships to disclose
Arturo Loaiza-Bonilla
No relevant relationships to disclose
Ikechukwu Immanuel Akunyili
No relevant relationships to disclose
Maria H. Restrepo
No relevant relationships to disclose
Jaime R. Merchan
No relevant relationships to disclose
Govindarajan Narayanan
No relevant relationships to disclose
Lorraine Portelance
No relevant relationships to disclose
Danny Sleeman
No relevant relationships to disclose
Joe U Levi
No relevant relationships to disclose
Caio Max S. Rocha Lima
No relevant relationships to disclose